Stavros G. Vizirgianakis - 15 May 2025 Form 4 Insider Report for Apyx Medical Corp (APYX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
19 May 2025, 16:31:06 UTC
Prior SEC filing
12 Jun 2025
Next SEC filing
18 Nov 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Stavros G. Vizirgianakis

Key filing fact

Stavros G. Vizirgianakis filed Form 4 for Apyx Medical Corp (APYX) on 19 May 2025.

Key facts

  • This page summarizes Stavros G. Vizirgianakis's Form 4 filing for Apyx Medical Corp (APYX).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 19 May 2025, 16:31.

Change

  • Previous filing in this sequence was filed on 12 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001559834 Primary reporting owner

Vizirgianakis Stavros G.

Relationship
Director
Address
C/O APYX MEDICAL CORPORATION, 5115 ULMERTON ROAD, CLEARWATER
Signature
/s/ Stavros G. Vizirgianakis
Signature date
19 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APYX transaction Derivative

Stock Option (Option to Buy)

Award

Transaction value
$0
Shares
+128,000
Change %
Price
$0.000000
Shares after
128,000
Date
15 May 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
128,000
Exercise price
$1.48
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Reporting person was granted a stock option which shall vest ratably over a twelve (12) month period and shall become fully vested and fully exercisable on the first anniversary of the date of grant.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .